DrugCite
Search

FEIBA VH IMMUNO

Adverse Events
Drug Profile
Learn More
Reference
About Results
Comments

Feiba Vh Immuno Adverse Events Reported to the FDA Over Time

How are Feiba Vh Immuno adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Feiba Vh Immuno, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Feiba Vh Immuno is flagged as the suspect drug causing the adverse event.

Most Common Feiba Vh Immuno Adverse Events Reported to the FDA

What are the most common Feiba Vh Immuno adverse events reported to the FDA?

Condition Aggravated
21 (5.66%)
Drug Ineffective
18 (4.85%)
Factor Viii Inhibition
17 (4.58%)
Haemorrhage
13 (3.5%)
Disseminated Intravascular Coagulat...
11 (2.96%)
Myocardial Infarction
11 (2.96%)
Pneumonia
10 (2.7%)
Vomiting
10 (2.7%)
Thrombosis
9 (2.43%)
Cerebral Haemorrhage
8 (2.16%)
Pyrexia
8 (2.16%)
Show More Show More
Hypersensitivity
7 (1.89%)
Chills
6 (1.62%)
Haemorrhage Subcutaneous
6 (1.62%)
Nausea
6 (1.62%)
Respiratory Failure
6 (1.62%)
Chest Pain
5 (1.35%)
Headache
5 (1.35%)
Bone Disorder
4 (1.08%)
Capillary Leak Syndrome
4 (1.08%)
Femur Fracture
4 (1.08%)
Haemothorax
4 (1.08%)
Hepatitis C
4 (1.08%)
Mass
4 (1.08%)
Multi-organ Failure
4 (1.08%)
Oedema
4 (1.08%)
Throat Tightness
4 (1.08%)
Abdominal Pain
3 (.81%)
Dyspnoea
3 (.81%)
Haemolytic Uraemic Syndrome
3 (.81%)
Haemorrhage Intracranial
3 (.81%)
Muscle Haemorrhage
3 (.81%)
Platelet Count Decreased
3 (.81%)
Pulmonary Embolism
3 (.81%)
Tachycardia
3 (.81%)
Thrombophlebitis Superficial
3 (.81%)
Vision Blurred
3 (.81%)
Acute Hiv Infection
2 (.54%)
Acute Myocardial Infarction
2 (.54%)
Alanine Aminotransferase Increased
2 (.54%)
Amnesia
2 (.54%)
Anaphylactic Reaction
2 (.54%)
Animal Bite
2 (.54%)
Anti Factor Viii Antibody Positive
2 (.54%)
Anxiety
2 (.54%)
Aspartate Aminotransferase Increase...
2 (.54%)
Blood Pressure Increased
2 (.54%)
Chest Discomfort
2 (.54%)
Coagulopathy
2 (.54%)
Death
2 (.54%)
Dizziness
2 (.54%)
Eye Swelling
2 (.54%)
Haematoma
2 (.54%)
Head Injury
2 (.54%)
Hepatic Failure
2 (.54%)
Hyperaemia
2 (.54%)
Hypoaesthesia
2 (.54%)
Incorrect Drug Administration Rate
2 (.54%)
Infusion Related Reaction
2 (.54%)
Infusion Site Rash
2 (.54%)
Infusion Site Swelling
2 (.54%)
Lip Swelling
2 (.54%)
Liver Disorder
2 (.54%)
Malignant Ascites
2 (.54%)
Ocular Hyperaemia
2 (.54%)
Oedema Peripheral
2 (.54%)
Pain
2 (.54%)
Pain In Extremity
2 (.54%)
Peripheral Ischaemia
2 (.54%)
Post Procedural Complication
2 (.54%)
Pulmonary Oedema
2 (.54%)
Renal Disorder
2 (.54%)
Renal Failure Acute
2 (.54%)
Renal Impairment
2 (.54%)
Restlessness
2 (.54%)
Sinusitis
2 (.54%)
Swelling Face
2 (.54%)
Urticaria
2 (.54%)
Abnormal Sensation In Eye
1 (.27%)
Anaemia
1 (.27%)
Appendicitis
1 (.27%)
Arrhythmia
1 (.27%)
Back Pain
1 (.27%)
Blood Culture Positive
1 (.27%)
Blood Pressure Decreased
1 (.27%)
C-reactive Protein Increased
1 (.27%)
Cardiac Failure Congestive
1 (.27%)
Catheter Related Complication
1 (.27%)
Catheter Related Infection
1 (.27%)
Central Line Infection
1 (.27%)
Cerebrovascular Accident
1 (.27%)
Choking
1 (.27%)
Coagulation Factor Viii Level Incre...
1 (.27%)
Compartment Syndrome
1 (.27%)
Deafness
1 (.27%)
Deep Vein Thrombosis
1 (.27%)
Disease Progression
1 (.27%)
Drug Effect Decreased
1 (.27%)
Drug Hypersensitivity
1 (.27%)
Drug Intolerance
1 (.27%)
Electrocardiogram T Wave Inversion
1 (.27%)

ExportShare/Embed GraphExport Export Data

This graph shows the top adverse events submitted to the FDA for Feiba Vh Immuno, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Feiba Vh Immuno is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Feiba Vh Immuno

What are the most common Feiba Vh Immuno adverse events reported to the FDA?

Show More Show More

ExportShare/Embed Graph Export Export Data

This graph shows the top categories of adverse events submitted to the FDA for Feiba Vh Immuno, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Feiba Vh Immuno is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Common Uses of Feiba Vh Immuno According to Those Reporting Adverse Events

Why are people taking Feiba Vh Immuno, according to those reporting adverse events to the FDA?

Factor Viii Deficiency
32
Haemophilia A With Anti Factor Viii
13
Factor Viii Inhibition
13
Haemostasis
12
Haemophilia
11
Haemorrhage
11
Show More Show More
Acquired Haemophilia
10
Haemarthrosis
7
Post Procedural Haemorrhage
7
Prophylaxis
6
Joint Surgery
6
Haemophilia B With Anti Factor Ix
6
Haematuria
5
Off Label Use
5
Drug Use For Unknown Indication
4
Haematoma
3
Haemorrhage Control
3
Factor Ix Inhibition
3
Gastrointestinal Haemorrhage
2
Abnormal Clotting Factor
2
Factor Vii Deficiency
2
Haematemesis
1
Retroperitoneal Haematoma
1
Muscle Haemorrhage
1
Factor Ix Deficiency
1
Fracture
1
Tongue Haemorrhage
1
Soft Tissue Haemorrhage
1
Haemophilia B Without Inhibitors
1
Haemorrhage Subcutaneous
1
Epistaxis
1
Drug Administration Error
1
Sigmoidectomy
1

Feiba Vh Immuno Case Reports

What Feiba Vh Immuno safety concerns are being reported by doctors and researchers in the medical literature?

Powered by Google

About Results

This report contains aggregated drug side effects and adverse events for Feiba Vh Immuno. The data has been pulled from the United States Food and Drug Administration's (US FDA) Adverse Event Reporting System (AERS), a database containing more than 4,000,000 adverse event reports.

DrugCite expands your query using the Unified Medical Language System (UMLS) to include generic drugs and primary active ingredients. While the core of DrugCite's advanced drug filtering algorithm is based on the industry standard UMLS, DrugCite's proprietary filtering system also includes dozens of additional steps to reconcile malformed drug names in the FDA's data.

DrugCite only counts a drug if the submitter of the adverse event indicates that the drug is suspected to have caused the adverse event.

Depending on how the data is aggregated, different counts may occur. When someone submits an adverse event to the FDA, the submitter can attribute multiple adverse events to one or more drugs. For example, an individual taking Paxil could submit the adverse events "anxiety" and "suicidal ideation" for the same individual safety report (ISR). This means when DrugCite aggregates by adverse event, two distinct adverse events are counted in the adverse event graph; once for "anxiety" and again for "suicidal ideation". However, when DrugCite aggregates by individual safety reports irrespective of the details of the adverse events contained within the safety report, the report is only counted once.

Comments

Share your experience with Feiba Vh Immuno.